# Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

> **NCT02766608** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 2389 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disorder

## Interventions

- **DRUG:** BFF MDI 320/9.6 μg
- **DRUG:** BFF MDI 160/9.6 μg
- **DRUG:** FF MDI 9.6 μg
- **DRUG:** BD MDI 320 μg
- **DRUG:** Symbicort® TBH 400/12 μg BID

## Key facts

- **NCT ID:** NCT02766608
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2017-12-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 2389 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766608, "Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02766608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*